Vasculitis in the Central Nervous System: Etiology, Characteristics, and Outcomes in a Large Single-Center Cohort.

central nervous system vasculitis primary angiitis of the central nervous system secondary vasculitis vasculitis

Journal

The Neurohospitalist
ISSN: 1941-8744
Titre abrégé: Neurohospitalist
Pays: United States
ID NLM: 101558199

Informations de publication

Date de publication:
Apr 2024
Historique:
pmc-release: 01 04 2025
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 26 4 2024
Statut: ppublish

Résumé

For the management of central nervous system (CNS) vasculitis, it is crucial to differentiate between primary and secondary CNS vasculitis and to understand the respective etiologies. We assessed the etiology, characteristics, and outcomes of patients with CNS vasculitis. A single-center retrospective chart review was conducted at the University of Utah, Department of Neurology, between February 2011 and October 2022. The median age of the 44 included patients at diagnosis was 54 years; 25.0% were men. Compared to primary CNS vasculitis, secondary CNS vasculitis exhibits higher fever incidence (observed in infectious and connective tissue disorder [CTD]-associated vasculitis), low glucose levels (mostly in infectious vasculitis) and unique cerebrospinal fluid oligoclonal bands (observed in infectious and CTD-associated vasculitis). Patients with inflammatory cerebral amyloid angiopathy (CAA) were older and more commonly had microhemorrhage than primary angiitis of the CNS (PACNS). All patients with CTD-associated vasculitis had a known history of CTD at presentation. Brain biopsies were performed on 10 of 17 PACNS patients and 4 of 8 inflammatory CAA patients, confirming vasculitis in 7 and 4 patients, respectively. Intravenous methylprednisolone was the predominant induction therapy (63.6%), and cyclophosphamide was the most used adjunctive therapy. Cyclophosphamide, rituximab, azathioprine, and mycophenolate mofetil were utilized as maintenance therapy, often with concurrent prednisone. Patients with inflammatory CAA had a higher tendency for relapse rates than PACNS. This study highlights the variations in patients' characteristics, symptoms, and treatment for CNS vasculitis. Understanding these differences can lead to more efficient diagnostic and management strategies.

Sections du résumé

Background and Purpose UNASSIGNED
For the management of central nervous system (CNS) vasculitis, it is crucial to differentiate between primary and secondary CNS vasculitis and to understand the respective etiologies. We assessed the etiology, characteristics, and outcomes of patients with CNS vasculitis.
Methods UNASSIGNED
A single-center retrospective chart review was conducted at the University of Utah, Department of Neurology, between February 2011 and October 2022.
Results UNASSIGNED
The median age of the 44 included patients at diagnosis was 54 years; 25.0% were men. Compared to primary CNS vasculitis, secondary CNS vasculitis exhibits higher fever incidence (observed in infectious and connective tissue disorder [CTD]-associated vasculitis), low glucose levels (mostly in infectious vasculitis) and unique cerebrospinal fluid oligoclonal bands (observed in infectious and CTD-associated vasculitis). Patients with inflammatory cerebral amyloid angiopathy (CAA) were older and more commonly had microhemorrhage than primary angiitis of the CNS (PACNS). All patients with CTD-associated vasculitis had a known history of CTD at presentation. Brain biopsies were performed on 10 of 17 PACNS patients and 4 of 8 inflammatory CAA patients, confirming vasculitis in 7 and 4 patients, respectively. Intravenous methylprednisolone was the predominant induction therapy (63.6%), and cyclophosphamide was the most used adjunctive therapy. Cyclophosphamide, rituximab, azathioprine, and mycophenolate mofetil were utilized as maintenance therapy, often with concurrent prednisone. Patients with inflammatory CAA had a higher tendency for relapse rates than PACNS.
Conclusions UNASSIGNED
This study highlights the variations in patients' characteristics, symptoms, and treatment for CNS vasculitis. Understanding these differences can lead to more efficient diagnostic and management strategies.

Identifiants

pubmed: 38666288
doi: 10.1177/19418744231223283
pii: 10.1177_19418744231223283
pmc: PMC11040621
doi:

Types de publication

Journal Article

Langues

eng

Pagination

129-139

Informations de copyright

© The Author(s) 2023.

Déclaration de conflit d'intérêts

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Yoji Hoshina (Y)

Department of Neurology, University of Utah, Salt Lake City, UT, USA.

Alen Delic (A)

Department of Neurology, University of Utah, Salt Lake City, UT, USA.

Ka-Ho Wong (KH)

Department of Neurology, University of Utah, Salt Lake City, UT, USA.

Stephanie Lyden (S)

Department of Neurology, University of Utah, Salt Lake City, UT, USA.

Robert Kadish (R)

Department of Neurology, University of Utah, Salt Lake City, UT, USA.

Tammy L Smith (TL)

Department of Neurology, University of Utah, Salt Lake City, UT, USA.
George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA.
Department of Pathology, University of Utah, Salt Lake City, UT, USA.

Melissa A Wright (MA)

Department of Neurology, University of Utah, Salt Lake City, UT, USA.

Daisuke Shimura (D)

Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA.

Stacey L Clardy (SL)

Department of Neurology, University of Utah, Salt Lake City, UT, USA.
George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA.

Classifications MeSH